"Indans" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Aryl CYCLOPENTANES that are a reduced (protonated) form of INDENES.
| Descriptor ID |
D007189
|
| MeSH Number(s) |
D02.455.426.559.847.486.487 D04.615.486.487
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indans".
Below are MeSH descriptors whose meaning is more specific than "Indans".
This graph shows the total number of publications written about "Indans" by people in this website by year, and whether "Indans" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indans" by people in Profiles.
-
Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
-
Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease. Dig Dis Sci. 2024 Jun; 69(6):2044-2054.
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
-
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
-
Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.
-
A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2022 May; 16(5):411-423.
-
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
-
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291.
-
Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129.